

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Carmustine. [Updated 2021 Aug 16]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Carmustine

Revised: August 16, 2021.

CASRN: 154-93-8

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of carmustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as carmustine.[1] The manufacturer recommends that breastfeeding be discontinued during carmustine therapy and for 1 month after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Some evidence indicates that carmustine can increase serum prolactin.[2] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

- 1. Pistilli B, Bellettini G, Giovannetti E, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013;39:207–11. PubMed PMID: 23199900.
- 2. Constine LS, Rubin P, Woolf PD, et al. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol. 1987;5:1841–51. PubMed PMID: 3681371.

Substance Identification

Substance Name

Carmustine

CAS Registry Number

154-93-8

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents, Alkylating

Nitrosourea Compounds